Αποτελέσματα Αναζήτησης
The mean dose of procainamide was 1207 ± 487 mg/day. Procainamide therapy significantly decreased ICD interventions (median 5 [0–22.5] vs 15.5 [3–32.25], P < .05). Procainamide also decreased the total number of VT/VF episodes (median 5.5 [0.75–30] vs 19 [7.5–30], P < .05). Only 3 patients (8.8%) presented severe side effects (dyspnea ...
For monomorphic ventricular tachycardia with a pulse or polymorphic ventricular tachycardia with a pulse (not due to torsades de pointes), administer procainamide at 1-2 grams over 5-60 minutes. See the dosage table above for further details.
8 Μαΐ 2023 · Procainamide is a medication used to manage and treat ventricular arrhythmias, supraventricular arrhythmias, atrial flutter, atrial fibrillation, AV nodal re-entrant tachycardia, and Wolf-Parkinson-White syndrome. It is a Class 1A antiarrhythmic agent.
unfeasible, not readily available, or unsuccessful, and treat-ment with beta-blockers and amiodarone proves ineffective, procainamide might represent an alternative strategy for pre-venting the recurrence of ventricular tachyarrhythmias and ICD discharges.
Procainamide was more effective by 1.5 hours in those with AF than AFL/both: 46.3% vs 22.2% (P<0.01). All predictors except dose were associated with higher adjusted odds of cardioversion by 1.5 hours (Table).
20 Φεβ 2021 · Procainamide was administered within the scanner with intermittent intravenous boluses of 50 mg every minute until the complete suppression of PVCs up to a maximum dose of 10 mg/kg during continuous ECG monitoring and non-invasive blood pressure monitoring every minute.
19 Απρ 2019 · Procainamide for termination of stable VT is associated with fewer adverse cardiac events and may be more effective for cardioversion compared to amiodarone. NNT of four in favor of procainamide to convert one more patient with stable VT to baseline rhythm.
